{"name":"Beijing Suncadia Pharmaceuticals Co., Ltd","slug":"beijing-suncadia-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"beijingsuncadia.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SHR-1918 Injection","genericName":"SHR-1918 Injection","slug":"shr-1918-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-2004 injection","genericName":"SHR-2004 injection","slug":"shr-2004-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","genericName":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","slug":"enoxaparin-sodium-injection-rivaroxaban-tablets","indication":"Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SHR-6934 injection","genericName":"SHR-6934 injection","slug":"shr-6934-injection","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SHR-1918 Injection","genericName":"SHR-1918 Injection","slug":"shr-1918-injection","phase":"phase_3","mechanism":"SHR-1918 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"SHR-2004 injection","genericName":"SHR-2004 injection","slug":"shr-2004-injection","phase":"phase_3","mechanism":"SHR-2004 injection is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","genericName":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","slug":"enoxaparin-sodium-injection-rivaroxaban-tablets","phase":"phase_2","mechanism":"Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly.","indications":["Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation"],"catalyst":""},{"name":"SHR-6934 injection","genericName":"SHR-6934 injection","slug":"shr-6934-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}